Onesource Specialty Pharma Ltd

OneSource Specialty Pharma announced that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Sterile Product Division facility (SPD) of OneSource Specialty Pharma located at Opp. IIM, Bilekahalli, Bannerghatta Road, Bengaluru, 560076 from 22 June 2026 to 30 June 2026. The inspection has concluded with one observation. The Company will respond to the observation comprehensively to FDA within the stipulated time frame.

Net profit of OneSource Specialty Pharma declined 95.33% to Rs 4.60 crore in the quarter ended March 2026 as against Rs 98.50 crore during the previous quarter ended March 2025. Sales rose 0.53% to Rs 428.22 crore in the quarter ended March 2026 as against Rs 425.95 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 73.80 crore in the year ended March 2026 as against net loss of Rs 17.97 crore during the previous year ended March 2025. Sales declined 1.61% to Rs 1421.59 crore in the year ended March 2026 as against Rs 1444.85 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales428.22425.95 1 1421.591444.85 -2 OPM %21.4742.85 -21.4032.29 - PBDT71.50151.99 -53 197.06317.67 -38 PBT-0.3283.50 PL -82.0343.78 PL NP4.6098.50 -95 -73.80-17.97 -311 Powered by Capital Market - Live

OneSource Specialty Pharma has allotted 3,150 equity shares under ESOP on 13 May 2026. With this allotment, the paid up equity share capital has increased to 114,645,801 equity shares of Re. 1/- each.

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on 13 May 2026.

OneSource Specialty Pharma announced that its partner Dr. Reddy's Laboratories has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic'. OneSource serves as the CDMO partner on this program, providing scale-up and manufacturing support. The partnership is designed to ensure reliable and scalable commercial supply from OneSource's US-FDA approved flagship manufacturing facility in Bengaluru. Neeraj Sharma, CEO & MD, OneSource Speciality Pharma Limited, speaking on the development, said: 'We are pleased to announce that our partner Dr. Reddy's has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic'. This approval further strengthens our collaboration, combining Dr. Reddy's expertise in peptide development with OneSource's CDMO capabilities.'

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval for an Abbreviated New Drug Application (ANDA) for a generic version of Ozempic' (Semaglutide Injection). OneSource is the contract development and manufacturing organization (CDMO) partner for this product. This milestone highlights a closely integrated development-to-submission model: Orbicular led the product development and technical program for this complex peptide, while OneSource supported the program as the CDMO partner, providing end-to-end manufacturing capabilities for the U.S. market filing. The collaboration is designed to ensure reliable commercial supply from OneSource's US-FDA approved flagship site in Bangalore. Neeraj Sharma, CEO & MD, OneSource Speciality Pharma, speaking on the development, said: 'We are pleased to announce that our partner Orbicular, along with its front-end partner (the ANDA holder), has received tentative approval for a generic version of Ozempic' (Semaglutide Injection). This milestone reflects Orbicular's scientific expertise and OneSource's CDMO capabilities, supported by our US-FDA approved manufacturing site.'

OneSource Specialty Pharma announced that NSE Sustainability Ratings & Analytics has, independently assigned Environmental, Social and Governance ('ESG') Rating of '73' (Rating Category: Leader) to the company for the financial year FY25.

OneSource Speciality Pharma announced it has received Saudi Food and Drug Authority (SFDA) approval of its generic Ozempic' (semaglutide) in Saudi Arabia, clearing the path for commercialsing the product with Hikma Pharmaceuticals PLC (Hikma) as their exclusive commercialisation partner for the Middle East and North Africa (MENA). The approval represents an important entry for OneSource into the Kingdom of Saudi Arabia, one of the largest markets for GLP-1 therapies, positioning the exclusive partnership to capitalise on rising demand for this product and underscoring the shared ambition of both companies to increase access to high-quality affordable generic alternatives to patients across the region. Under the exclusive agreement, OneSource will manufacture and supply semaglutide from its state of-the-art integrated Biologics and Drug-Device Combination facility in Bengaluru and Hikma, the largest pharmaceutical company in MENA based on sales1, will use its extensive commercial reach and institutional relationships in the region to scale access across both private and institutional channels.Powered by Capital Market - Live

SBFC Finance Ltd, Syngene International Ltd, JSW Energy Ltd and Avantel Ltd are among the other losers in the BSE's 'A' group today, 27 January 2026.OneSource Specialty Pharma Ltd tumbled 18.35% to Rs 1169.8 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 1.17 lakh shares were traded on the counter so far as against the average daily volumes of 6142 shares in the past one month.SBFC Finance Ltd lost 11.37% to Rs 90.05. The stock was the second biggest loser in 'A' group.On the BSE, 26.8 lakh shares were traded on the counter so far as against the average daily volumes of 2.51 lakh shares in the past one month.Syngene International Ltd crashed 10.03% to Rs 488.15. The stock was the third biggest loser in 'A' group.On the BSE, 6.61 lakh shares were traded on the counter so far as against the average daily volumes of 36060 shares in the past one month.JSW Energy Ltd dropped 8.49% to Rs 437.9. The stock was the fourth biggest loser in 'A' group.On the BSE, 9.32 lakh shares were traded on the counter so far as against the average daily volumes of 91637 shares in the past one month.Avantel Ltd pared 7.26% to Rs 126.45. The stock was the fifth biggest loser in 'A' group.On the BSE, 4.58 lakh shares were traded on the counter so far as against the average daily volumes of 1.07 lakh shares in the past one month.Powered by Capital Market - Live

Net Loss of OneSource Specialty Pharma reported to Rs 88.70 crore in the quarter ended December 2025 as against net loss of Rs 68.85 crore during the previous quarter ended December 2024. Sales declined 26.04% to Rs 290.34 crore in the quarter ended December 2025 as against Rs 392.56 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales290.34392.56 -26 OPM %5.9736.14 - PBDT-16.28102.78 PL PBT-85.9234.02 PL NP-88.70-68.85 -29 Powered by Capital Market - Live